Nyxoah Reports Revenue of 10 Million Euros in 2025
Belgian medical technology company Nyxoah has released its unaudited preliminary results for the fiscal year 2025, marked by its first full quarter of commercialization in the United States following FDA approval.
According to the press release dated January 12, 2026, Nyxoah recorded a global revenue exceeding 10 million euros for the entire fiscal year 2025. This performance is based on the launch of its Genio system in the American market and the continuation of its international geographical expansion. The company indicates that the fourth quarter of 2025 was its first full quarter of commercialization in the United States following the FDA approval. The company specifies that these preliminary results are unaudited and subject to revisions until the publication of its complete financial results in its annual report on Form 20-F.
Revenue Forecasts for Early 2026
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The company has communicated revenue forecasts for the first quarter of 2026, however, it did not specify the amounts in the press release. Nyxoah mentions having a waiting list for additional surgeon training and for patients scheduled for implants. The group reports initial results obtained by its American patients, without providing numerical data on this matter. The estimates concerning revenue, cash, cash equivalents, and financial assets presented remain preliminary, the company clarifies.
Participation in the 44th Annual J.P. Morgan Healthcare Conference
Nyxoah will participate in the 44th annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, according to the press release. The company plans to make a presentation at 12:00 PM Pacific Time, accessible via webcast on the Investor Relations page of its website. The Belgian company, listed on Euronext Brussels and on the Nasdaq, develops and markets the Genio system, a hypoglossal nerve neurostimulation therapy designed to treat obstructive sleep apnea. The system received CE marking in 2019 and FDA approval in August 2025 for a subgroup of adult patients with moderate to severe obstructive sleep apnea.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: T3 2026
Key reported figures
Revenue: 9,2 millions d'euros
Quarterly revenue: 9,2 millions d'euros
Revenue growth: 366,5 %
Guidance from the release
Bien que nous soyons déçus d'ajuster nos prévisions de chiffre d'affaires
Risks mentioned
Ajustement à la baisse des prévisions de chiffre d'affaires (de 36-40 M€ à 33-35 M€)
Trajectoire de croissance inférieure aux attentes pour l'exercice 2026
Dépendance à la ramp-up des États-Unis reflétant les cycles historiques d'une nouvelle technologie
Opportunities identified
Supplément PMA soumis à la FDA pour étendre l'indication américaine aux patients atteints de collapsus concentrique complet
Croissance séquentielle de 29 % du chiffre d'affaires aux États-Unis au T3 2026
Expansion du nombre de chirurgiens formés (342 cumulés) et comptes activés (233 à fort volume) aux États-Unis
Outlook / guidance
Expected revenue: 34 millions d'euros
Management commentary: The Company now expects global net revenue for the full year 2026 to be in the range of €33 million to €35 million, compared to €36 million to €40 million previously.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
